Usana Health Sciences Azioni (NYSE: USNA)

Ultime notizie per Usana Health Sciences (NYSE:USNA) Azioni

Usana Health Sciences

Usana Health Sciences Inc is a U.S.-based company that is principally engaged in developing, manufacturing, and selling science-based nutritional and personal-care products. The company operates through direct selling. It owns a number of product lines, such as Essentials, which contains core vitamin and mineral supplements; Optimizers, which includes targeted supplements for individuals' health and nutritional needs; Foods, which consists of low-glycemic meal replacement shakes, snack bars, and other related products; and Sense Beautiful Science, which contains personal-care products related to skin and hair. The company conducts business worldwide, including Asia-Pacific, the Americas, and Europe.

Usana Health Sciences Inc

WIIM

USNA

USANA Health Sciences shares are trading higher following mixed Q3 financial results.

DA Davidson analyst Linda Bolton Weiser maintains Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) with a Neutral and lowers the price target from $38 to $35.

News

Price Target

Analyst Ratings

DA Davidson Maintains Neutral on Usana Health Sciences, Lowers Price Target to $35

Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.48 by 16.67 percent. This is a 5.08 percent decrease over earnings of $0.59 per share from the same period last year. The company reported quarterly sales of $200.22 million which missed the analyst consensus estimate of $205.77 million by 2.70 percent. This is a 6.16 percent decrease over sales of $213.37 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Usana Health Sciences Q3 EPS $0.56 Beats $0.48 Estimate, Sales $200.22M Miss $205.77M Estimate

Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) narrows FY2024 GAAP EPS guidance from $2.40-2.55 to $2.45 vs $2.50 analyst estimate. Narrows FY2024 sales outlook from $850.00 million-880.00 million to $850.00 million vs $861.94 million estimate.

Guidance

Usana Health Sciences Narrows FY2024 GAAP EPS Guidance from $2.40-2.55 to $2.45 vs $2.50 Est; Narrows FY2024 Sales Guidance from $850.00M-880.00M to $850.00M vs $861.94M Est.

Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) is preparing to release its quarterly earnings on Tuesday, 2024-10-22. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Usana Health Sciences to report an earnings per share (EPS) of $0.48.
Investors in Usana Health Sciences are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings Track Record</h3>
In the previous earnings release, the company missed EPS by $0.11, leading to a 3.2% drop in the share price the following trading session.
Here's a look at Usana Health Sciences's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.65</td>
<td>0.69</td>
<td>0.52</td>
<td>0.64</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.54</td>
<td>0.86</td>
<td>0.87</td>
<td>0.59</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>10.0%</td>
<td>4.0%</td>
<td>-18.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1729530097_0.png" alt="eps graph" />
<h3>Usana Health Sciences Share Price Analysis</h3>
Shares of Usana Health Sciences were trading at $35.85 as of October 18. Over the last 52-week period, shares are down 37.0%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/USNA/earnings">To track all earnings releases for Usana Health Sciences visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: Usana Health Sciences's Quarterly Earnings

Xencor (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xncr#NASDAQ">XNCR</a>) shares rallied 10.5% in the last trading session to close at $21.13. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock&#39;s 19.8% gain over the past four weeks.
This jump in share price came after the company announced that it was floating a secondary issue of common stock, along with pre-funded warrants, to raise nearly $175 million in gross proceeds. Management intends to issue more than 6.6 million shares at $18 apiece, along with pre-funded warrants to buy an additional 3 million shares for $17.99 a warrant.
Xencor will likely use these funds to support its pipeline development. Last week, the company unveiled details on four new programs targeting autoimmune diseases.
This biotech developing antibodies for severe autoimmune/allergic diseases and cancer is expected to post quarterly loss of $1.01 per share in its upcoming report, which represents a year-over-year change of -152.5%. Revenues are expected to be $7.74 million, down 86.9% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Xencor, the consensus EPS estimate for the quarter has been revised 0.8% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn&#39;t usually translate into price appreciation. So, make sure to keep an eye on XNCR going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold).
Xencor belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, USANA Health Sciences (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/usna#NYSE">USNA</a>), closed the last trading session 0.2% lower at $37.28. Over the past month, USNA has returned -3%.
For USANA Health, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.49. This represents a change of -17% from what the company reported a year ago. USANA Health currently has a Zacks Rank of #4 (Sell).
<a href="https://www.zacks.com/stock/news/2334996/xencor-xncr-surges-10-5-is-this-an-indication-of-further-gains?cid=CS-BENZ-FT-tale_of_the_tape|daily_price_change_5%-2334996">To read this article on Zacks.com click here.</a>

Biotech

Small Cap

Management

Markets

Trading Ideas

General

XNCR

Xencor Surges 10.5%: Is This an Indication of Further Gains?

DA Davidson analyst Linda Bolton Weiser maintains Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) with a Neutral and lowers the price target from $46 to $38.

DA Davidson Maintains Neutral on Usana Health Sciences, Lowers Price Target to $38

Usana Health Sciences shares are trading lower after the company reported worse-than-expected Q2 financial results.

USANA Health Sciences Updates FY24 Net Sales Outlook From $850M - $920M To $850M - $880M (Est $883.518M) And EPS Outlook From $2.40 - $3.00 To $2.40 - $2.55 (Est $2.78)

Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) reported quarterly earnings of $0.54 per share which missed the analyst consensus estimate of $0.65 by 16.92 percent. The company reported quarterly sales of $212.869 million which missed the analyst consensus estimate of $221.032 million by 3.69 percent. This is a 10.64 percent decrease over sales of $238.202 million the same period last year.

Usana Health Sciences Q2 2024 GAAP EPS $0.54 Misses $0.65 Estimate, Sales $212.869M Miss $221.032M Estimate

Usana Health Sciences's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) short percent of float has risen 18.01% since its last report. The company recently reported that it has 276 thousand shares sold short, which is 2.49% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.29 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Usana Health Sciences Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1720791019_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Usana Health Sciences has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Usana Health Sciences's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Usana Health Sciences's peer group average for short interest as a percentage of float is 6.75%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Usana Health Sciences's Recent Short Interest

Taking a multivitamin <a href="https://www.benzinga.com/markets/emerging-markets/23/12/36205088/inside-the-multibillion-dollar-supplement-industry-trends-and-insights">once a day</a> has long been considered a path to better health, but a new study refutes that widely held belief.
A study published in JAMA Network Open on Wednesday revealed that after tracking nearly 400,000 healthy adults for over 20 years, researchers found no link between regular multivitamin use and a lower risk of death, <a href="https://www.nih.gov/news-events/news-releases/healthy-adults-taking-multivitamins-daily-not-associated-lower-risk-death#:~:text=The%20analysis%20showed%20that%20people,heart%20disease%2C%20or%20cerebrovascular%20diseases">according </a>to the National Institutes of Health.
The study was led by researchers at the National Institutes of Health's National Cancer Institute.
Also Read: <a href="https://www.benzinga.com/markets/cannabis/23/07/33309720/healthcare-advocates-united-a-push-for-congress-to-recognize-cbd-as-dietary-supplements">Healthcare Advocates United: A Push For Congress To Recognize CBD As Dietary Supplements</a>
&#8220;The analysis showed that people who took daily multivitamins did not have a lower risk of death from any cause than people who took no multivitamins,&#8221; Erikka Loftfield, Ph.D., M.P.H., a researcher with the division of cancer epidemiology and genetics at the National Cancer Institute, wrote in the study.
&#8220;There were also no differences in mortality from cancer, heart disease, or cerebrovascular diseases. The results were adjusted for factors such as race and ethnicity, education, and diet quality.&#8221;
Loftfield also emphasized the importance of assessing the risk of death associated with multivitamin use in different populations, such as those with documented nutritional deficiencies. She highlighted the need to explore the potential impact of regular multivitamin use on aging-related health conditions.
Price Action: Despite the study&#8217;s findings on multivitamin use, related health and wellness companies saw varied market reactions. By Thursday&#8217;s afternoon trading, BellRing Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRBR#NYSE">BRBR</a>) gained 1.08% to $57.89, Herbalife Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) slipped 1.03% to $10.52, and USANA Health Sciences, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) was up 1% to $45.44.
Invesco S&amp;P SmallCap Consumer Staples ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSCC#NASDAQ">PSCC</a>) slipped 0.09% by early afternoon, while VegTech Plant-based Innovation &amp; Climate ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EATV#NYSE">EATV</a>) remained unchanged and Invesco Food &amp; Beverage ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBJ#NYSE">PBJ</a>) declined 0.68%.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/03/31554925/gianni-di-poce-rings-the-bell-on-bellring-brands-calls-for-42-returns">Gianni Di Poce Rings The Bell On BellRing Brands, Calls For 42% Returns</a></li>
</ul>
Photo: Shutterstock

Health Care

ETFs

BRBR

Advisors Series Trust VegTech Plant-based Innovation & Climate ETF

EATV

PSCC

Multivitamins Show No Link To 'Lower Risk of Death,' Study Finds

On June 12, a recent SEC filing unveiled that MYRON WENTZ, 10% Owner at Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) made an insider sell.
What Happened: WENTZ's recent move involves selling 3,700 shares of Usana Health Sciences. This information is documented in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000896264/000110465924070582//Archives/edgar/data/896264/000110465924070582/0001104659-24-070582-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The total value is $179,857.
Tracking the Wednesday's morning session, Usana Health Sciences shares are trading at $47.16, showing a down of 0.0%.
<h3>Delving into Usana Health Sciences's Background</h3>
Usana Health Sciences Inc is a U.S.-based company that is principally engaged in developing, manufacturing, and selling science-based nutritional and personal-care products. The company operates through direct selling. It owns a number of product lines, such as Essentials, which contains core vitamin and mineral supplements; Optimizers, which includes targeted supplements for individuals' health and nutritional needs; Foods, which consists of low-glycemic meal replacement shakes, snack bars, and other related products; and Sense Beautiful Science, which contains personal-care products related to skin and hair. The company conducts business worldwide, including Asia-Pacific, the Americas, and Europe.
<h3>A Deep Dive into Usana Health Sciences's Financials</h3>
Revenue Challenges: Usana Health Sciences's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -8.28%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 81.09%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Usana Health Sciences's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 0.86.
</li>
</ul>
Debt Management: Usana Health Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.0.
Assessing Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 14.69 is lower than the industry average, implying a discounted valuation for Usana Health Sciences's stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 1.01 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 4.7 is below the industry average, indicating that it may be relatively undervalued compared to peers.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Exploring Key Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000896264">Check Out The Full List Of Usana Health Sciences's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Insider Unloading: MYRON WENTZ Sells $179K Worth Of Usana Health Sciences Shares

DOUG IIEKKING, Chief Financial Officer at Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>), disclosed an insider sell on May 7, according to a recent SEC filing.
What Happened: According to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000896264/000089626424000172//Archives/edgar/data/896264/000089626424000172/0000896264-24-000172-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday, IIEKKING sold 5,198 shares of Usana Health Sciences. The total transaction value is $232,676.
Tracking the Wednesday's morning session, Usana Health Sciences shares are trading at $44.74, showing a down of 0.0%.
<h3>Get to Know Usana Health Sciences Better</h3>
Usana Health Sciences Inc is a U.S.-based company that is principally engaged in developing, manufacturing, and selling science-based nutritional and personal-care products. The company operates through direct selling. It owns a number of product lines, such as Essentials, which contains core vitamin and mineral supplements; Optimizers, which includes targeted supplements for individuals' health and nutritional needs; Foods, which consists of low-glycemic meal replacement shakes, snack bars, and other related products; and Sense Beautiful Science, which contains personal-care products related to skin and hair. The company conducts business worldwide, including Asia-Pacific, the Americas, and Europe.
<h3>A Deep Dive into Usana Health Sciences's Financials</h3>
Revenue Growth: Usana Health Sciences displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 3.04%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: With a high gross margin of 81.09%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 0.86, Usana Health Sciences showcases strong earnings per share.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.0.
Assessing Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 13.94 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.96 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 5.27 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Delving Into the Significance of Insider Transactions</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Unlocking the Meaning of Transaction Codes</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000896264">Check Out The Full List Of Usana Health Sciences's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Usana Health Sciences Chief Financial Officer Sold $232K In Company Stock

Daniel Macuga, Chief Communications Officer at Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>), reported an insider sell on May 6, according to a new SEC filing. 
What Happened: After conducting a thorough analysis, Macuga sold 3,791 shares of Usana Health Sciences. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000896264/000089626424000160//Archives/edgar/data/896264/000089626424000160/0000896264-24-000160-index.htm">U.S. Securities and Exchange Commission</a> on Monday. The total transaction value is $178,716.
As of Tuesday morning, Usana Health Sciences shares are down by 0.0%, currently priced at $44.61.
<h3>Unveiling the Story Behind Usana Health Sciences</h3>
Usana Health Sciences Inc is a U.S.-based company that is principally engaged in developing, manufacturing, and selling science-based nutritional and personal-care products. The company operates through direct selling. It owns a number of product lines, such as Essentials, which contains core vitamin and mineral supplements; Optimizers, which includes targeted supplements for individuals' health and nutritional needs; Foods, which consists of low-glycemic meal replacement shakes, snack bars, and other related products; and Sense Beautiful Science, which contains personal-care products related to skin and hair. The company conducts business worldwide, including Asia-Pacific, the Americas, and Europe.
<h3>Financial Insights: Usana Health Sciences</h3>
Revenue Growth: Usana Health Sciences's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 3.04%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.
Navigating Financial Profits:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 81.09%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): Usana Health Sciences's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 0.86.
</li>
</ul>
Debt Management: Usana Health Sciences's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
Assessing Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 13.9, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 0.96 is lower than the industry average, implying a discounted valuation for Usana Health Sciences's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 5.24, Usana Health Sciences's EV/EBITDA ratio reflects a below-par valuation compared to industry averages signalling undervaluation
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
Insider transactions contribute to decision-making but should be supplemented by a comprehensive investment analysis.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Unlocking the Meaning of Transaction Codes</h3>
Navigating through the landscape of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000896264">Check Out The Full List Of Usana Health Sciences's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Unloading: Daniel Macuga Sells $178K Worth Of Usana Health Sciences Shares

DA Davidson analyst Linda Bolton Weiser maintains Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) with a Neutral and lowers the price target from $48 to $46.

DA Davidson Maintains Neutral on Usana Health Sciences, Lowers Price Target to $46

Usana Health Sciences shares are trading higher after the company reported better-than-expected Q1 financial results.

Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) reported quarterly earnings of $0.86 per share which beat the analyst consensus estimate of $0.69 by 24.64 percent. This is a 9.47 percent decrease over earnings of $0.95 per share from the same period last year. The company reported quarterly sales of $227.800 million which beat the analyst consensus estimate of $226.853 million by 0.42 percent. This is a 8.28 percent decrease over sales of $248.360 million the same period last year.

Usana Health Sciences Q1 2024 GAAP EPS $0.86 Beats $0.69 Estimate, Sales $227.800M Beat $226.853M Estimate

DA Davidson analyst Linda Bolton Weiser maintains Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) with a Neutral and lowers the price target from $53 to $48.

DA Davidson Maintains Neutral on Usana Health Sciences, Lowers Price Target to $48

RSPS: Consumer Staples Dashboard For October

USANA Health Sciences Q3 2024 Earnings Preview

USANA Health Sciences GAAP EPS of $0.56 beats by $0.08, revenue of $200M misses by $5.77M

Two estimates $2.49. Cuts FY24 revenue view to $850M from $850M-$880M, two estimates $861.94M. "Third quarter net sales were modestly below expecta...

Usana now sees FY24 EPS $2.45, previous view $2.40-$2.55

Reports Q3 revenue $200M, two estimates $205.77M. "Third quarter operating results reflected continued top line headwinds across many of our key ma...

Usana reports Q3 EPS 56c, two estimates 48c

USANA Health ( ($USNA) ) has shared an update. USANA Health Sciences reported a decline in Q3 2024 net sales to $200 million, down from $213 millio...

USANA Health Faces Q3 2024 Sales Decline Amid Challenges

Check out this evening's top movers from around Wall Street, compiled by The Fly.&nbsp;&nbsp; HIGHER AFTER EARNINGS –&nbsp; Stride&nbsp;(LRN)&nbsp;...

Closing Bell Movers: Starbucks falls 4% on negative pre-announcement

DA Davidson analyst Linda Bolton Weiser lowered the firm's price target on Usana (USNA) to $35 from $38 and keeps a Neutral rating on the shares af...

Usana price target lowered to $35 from $38 at DA Davidson

USANA Health Sciences, Inc. (USNA) Q3 2024 Earnings Call Transcript

FSTA: Consumer Staples Dashboard For November

COST

ENPH

EWBC

FSLR

FSTA

MANH

MDLZ

MNST

RSPS

SBUX

SEDG

VICR

Press Releases

USANA Executive Chairman Kevin Guest Shares 7 Steps to Soar Like Olympians

USANA Launches New, Innovative Skincare and Protein Products Resurfacing Serum and Whey Protein Isolate up the game for USANA

USANA Executive Chairman Kevin Guest Celebrates Entrepreneurs in Today's Business World

USANA-Sponsored Olympic and Paralympic Athletes Take Home 99 Combined Medals

Entertainment

USANA Executive Chairman Kevin Guest Celebrates Country Music Month, Mental Balance

USANA Schedules Third Quarter 2024 Earnings Release and Conference Call

11 USANA Products Now Listed on Prestigious Prescribers' Digital Reference®

USANA Health Sciences Reports Third Quarter 2024 Results

USANA Executive Chairman Kevin Guest Celebrates Gratitude Month

USANA Named Top Manufacturer in Utah for Third Time

BellRing Brands

Coty

Big Tree Cloud Holdings Limited - Ordinary Shares

Big Tree Cloud Holdings

Estee Lauder Companies, Inc. (The) Common Stock

Estee Lauder Cos

e.l.f. Beauty

Edgewell Personal Care Company Common Stock

Edgewell Personal Care

FitLife Brands

Herbalife

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Honest Co

Interparfums

Kenvue

Lifevantage

Medifast

Nature's Sunshine Products, Inc. - Common Stock

Natures Sunshine Products

Natural Health Trends Corp. - Commn Stock

Natural Health Trends

Nu Skin Enterprises

Olaplex Hldgs

Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares

Paranovus Enter

Safety Shot

The Beauty Health Company - Class A Common Stock

Beauty Health

Unilever

Veru

Waldencast

Yatsen Holding Limited American Depositary Shares, each representing twenty (20) Class A Ordinary Shares

Comments

Usana Health Sciences

Notizie

Ultime notizie per Usana Health Sciences (NYSE:USNA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO